Cipla signs exclusive licensing deal with SBP Group for HER2 ADC TQB2102

Strategic Transactions View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹1409.20

prior close

₹1420.90

announcement price

After-mkt

timing

Nifty 100market-0.3%+0.9% vs market

Pharmaceuticals peers, median of 175sector-0.3%+0.9% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty 100 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.1

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6-0.3+0.9-0.3+0.9

Next day

+0.0-0.8+0.8-0.5+0.5

-1.4-0.9-0.5+0.0-1.4

-1.7-0.8-0.9+0.2-1.9

-1.0-1.3+0.3+0.2-1.2

-1.8-1.7-0.1+0.9-2.7

-2.5-2.3-0.2+0.3-2.9

15d

-2.0-2.5+0.5+0.8-2.8

-4.6-6.8+2.2-1.2-3.4

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla signed an exclusive licensing deal with China's SBP Group for TQB2102, a HER2 bispecific antibody-drug conjugate for breast cancer. Cipla gets exclusive rights to develop and commercialise it in India, South Africa, and 5 other emerging markets. SBP Group's subsidiary CTTQ will manufacture and supply. TQB2102 has three Breakthrough Therapy Designations from China and targets HER2-low and HER2-positive cancers. No deal value disclosed.

Likely market impact

Boosts Cipla's oncology pipeline for emerging markets. No financial terms disclosed, so limited near-term earnings impact, but long-term growth optionality.